1-((R)-3-tert-Butoxy-2-methyl-propyl)-pyrrolidine | 72443-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-((R)-3-tert-Butoxy-2-methyl-propyl)-pyrrolidine
• 英文别名: 1-[(2R)-2-methyl-3-[(2-methylpropan-2-yl)oxy]propyl]pyrrolidine
• CAS: 72443-87-9
• 化学式: C₁₂H₂₅NO
• 分子量: 199.337
• InChiKey: PRGORGMHHPHTIR-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-((R)-3-tert-Butoxy-2-methyl-propyl)-pyrrolidine 在 三氟乙酸 作用下， 以82%的产率得到(R)-2-Methyl-3-pyrrolidin-1-yl-propan-1-ol
  参考文献：
  名称：

  Asymmetric reductions of .alpha.,.beta.-acetylenic ketones and acetophenone using lithium aluminum hydride complexed with optically active 1,3-amino alcohols

  摘要：

  DOI：

  10.1021/jo01292a006
• 作为产物：
  描述：

  四氢吡咯 、 (S)-1-tert-butoxy-2-methyl-3-(toluene-4-sulfonyloxy)-propane 以50%的产率得到1-((R)-3-tert-Butoxy-2-methyl-propyl)-pyrrolidine
  参考文献：
  名称：

  Asymmetric reductions of .alpha.,.beta.-acetylenic ketones and acetophenone using lithium aluminum hydride complexed with optically active 1,3-amino alcohols

  摘要：

  DOI：

  10.1021/jo01292a006

文献信息

• SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS
  申请人：Epizyme, Inc.

  公开号：US20200039961A1

  公开（公告）日：2020-02-06

  The present disclosure relates to substituted fused bi- or tri-heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering a substituted fused bi- or tri-heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
• COMBINATION THERAPIES WITH EHMT2 INHIBITORS
  申请人：Epizyme, Inc.

  公开号：US20200054635A1

  公开（公告）日：2020-02-20

  The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
• METHODS OF USING EHMT2 INHIBITORS
  申请人：Epizyme, Inc.

  公开号：US20200113901A1

  公开（公告）日：2020-04-16

  The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
• AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF
  申请人：Epizyme, Inc.

  公开号：US20200317642A1

  公开（公告）日：2020-10-08

  The present disclosure relates to amine-substituted heterocyclic compounds and derivatives thereof. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) by administering an amine-substituted heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
• METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES
  申请人：Epizyme, Inc.

  公开号：US20210213014A1

  公开（公告）日：2021-07-15

  The present disclosure relates to methods and compositions for treating immune-mediated diseases. In some aspects, the disclosure relates to methods for treating immune-mediated diseases by administering an EHMT2 inhibitor in combination with one or more treatment modalities (e.g. one or more therapeutic agents). In some aspects the immune-mediated disease is rheumatoid arthritis, multiple sclerosis, psoriasis, a psoriatic disorder, psoriatic arthritis, or an inflammatory bowel disease.